What Antengene does

Antengene Corporation Limited is a Hong Kong-listed (6996.HK) clinical- and commercial-stage biopharmaceutical company founded in 2017 that develops therapeutics for oncology and autoimmune diseases. The company's commercial product is XPOVIO (selinexor), the world's first approved orally-available selective XPO1 inhibitor, which is approved in 10 Asia Pacific markets for multiple myeloma and diffuse large B-cell lymphoma and included in national reimbursement schemes in five of those markets (mainland China, Taiwan, Australia, South Korea, Singapore). Beyond XPOVIO, Antengene maintains a clinical and preclinical pipeline spanning T-cell engagers, antibody-drug conjugates, and small molecules targeting solid tumors, hematologic malignancies, and B cell-related autoimmune diseases.

The company's central technology is the proprietary AnTenGager® TCE 2.0 platform, which generates T-cell engagers using a '2+1' bivalent binding architecture designed to address low-expressing antigens, steric hindrance masking technology, and proprietary CD3 sequences with fast on/off kinetics intended to minimize cytokine release syndrome. This platform has yielded multiple TCE candidates including ATG-201 (CD19/CD3, partnered with UCB), ATG-106 (CDH6/CD3, partnered with K2 Therapeutics), ATG-112 (ALPPL2/CD3), ATG-110 (LY6G6D/CD3), ATG-021 (GPRC5D/CD3), ATG-102 (LILRB4/CD3), and ATG-107 (FLT3/CD3). Outside the TCE franchise, Antengene is developing ATG-022 (a CLDN18.2 ADC in pivotal Phase III CLINCH-3 for gastric/gastroesophageal junction cancer) and ATG-037 (an oral small molecule CD73 inhibitor with demonstrated activity in checkpoint inhibitor-resistant tumors). The pipeline has produced 33 IND approvals across the U.S. and Asia.

Antengene operates a hybrid business model combining direct commercial sales of XPOVIO across Asia Pacific with an out-licensing strategy for proprietary pipeline assets to global pharmaceutical partners. The company typically conducts first-in-human trials in China and Australia before transferring development to licensing partners — recent deals include the UCB worldwide license for ATG-201 ($80M upfront plus over $1.1B in milestones) and the K2 Therapeutics license for ATG-106 and an undisclosed program (~$20M upfront plus up to $960.5M per program in milestones). XPOVIO commercialization in mainland China is executed through a partnership with Hansoh Pharma, and clinical collaborations with MSD (KEYTRUDA combinations) and Junshi Biosciences (JS207 combination) are intended to broaden the therapeutic reach of the pipeline within combination regimens.

Name

Antengene

Legal name

Antengene Corporation Limited

Website

https://antengene.com

Company type

Public

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Antengene is a Hong Kong-listed biopharmaceutical company developing oncology and autoimmune therapeutics, with commercial XPOVIO sales across 10 Asia Pacific markets and a proprietary AnTenGager® TCE 2.0 platform generating T-cell engagers, ADCs, and small molecules out-licensed to global partners.

Ownership category

akta.pro rank

Product category

Oncology Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Oncology drug development
• Bispecific antibody therapeutics
• T-cell engager platform
• Antibody-drug conjugates
• Cancer immunotherapy pipeline

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. XPOVIO (Selinexor) Product Sales: Commercial-stage revenue from XPOVIO sales across 10 Asia Pacific markets including mainland China, Taiwan, Hong Kong, Macau, South Korea, Singapore, Malaysia, Thailand, Indonesia, and Australia. Product is included in national reimbursement schemes in five markets.
2. Licensing and Milestone Payments: Upfront payments and potential milestone payments from out-licensing deals. Recent deals include UCB for ATG-201 ($80M upfront + $1.1B+ milestones) and K2 Therapeutics for ATG-106 ($20M upfront + $960.5M milestones per program).
3. Royalty Revenue: Tiered royalties on future net sales from licensed products including ATG-201 (UCB deal) and ATG-106 (K2 Therapeutics deal).

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Antengene is a commercial-stage biopharmaceutical company that develops and commercializes innovative oncology therapeutics. It sells XPOVIO (selinexor), the world's first approved oral selective XPO1 inhibitor, across 10 Asia Pacific markets for multiple myeloma and DLBCL, while advancing a pipeline of antibody-drug conjugates (e.g., ATG-022), oral small molecule inhibitors (ATG-037), and T-cell engagers built on its proprietary AnTenGager TCE 2.0 platform. The company also monetizes pipeline assets through out-licensing deals with global pharmaceutical partners.

Product overview

Antengene is a global, R&D-driven, commercial-stage biotech company that has evolved from an oncology and hematology focus to include autoimmune diseases. The company's portfolio spans from preclinical to commercial stages and consists of: (1) XPOVIO® (selinexor), the world's first approved orally-available selective XPO1 inhibitor, which is approved across 10 Asia Pacific markets for multiple myeloma and DLBCL; (2) a pipeline of investigational candidates including ATG-022 (Claudin 18.2 ADC) in pivotal Phase III for gastric cancer, ATG-037 (oral CD73 inhibitor) in clinical development for solid tumors, and ATG-201 (CD19/CD3 TCE) partnered with UCB for autoimmune diseases; (3) the proprietary AnTenGager® TCE 2.0 platform that generates multiple bispecific T-cell engagers (including ATG-106, ATG-112, ATG-207, ATG-110, ATG-021, ATG-102, and ATG-107) targeting various antigens for autoimmune diseases, solid tumors, and hematological malignancies; and (4) additional bispecific antibodies like ATG-101 (PD-L1/4-1BB) and ATG-125 (B7-H3/PD-L1 ADC). The AnTenGager® platform, featuring '2+1' bivalent binding and steric hindrance masking technology, serves as a differentiated technology foundation underpinning the company's T-cell engager programs.

Differentiator

Problem solved

Functional benefit

Brands

• XPOVIO: Brand name for selinexor, the world's first orally-available selective XPO1 inhibitor, approved across multiple Asia Pacific markets for multiple myeloma and DLBCL
• 希维奥
• AnTenGager
• AnTenGager TCE 2.0

Products and services

• XPOVIO (Selinexor) The world's first approved orally-available selective inhibitor of nuclear export protein XPO1, approved across multiple Asia Pacific markets for treatment of multiple myeloma and diffuse large B-cell lymphoma (DLBCL).
• ATG-022 (Claudin 18.2 ADC) Claudin 18.2 antibody-drug conjugate for solid tumors including gastric/gastroesophageal junction cancer. Demonstrated objective response rates of 46.7% and 40.0% at 1.8 mg/kg and 2.4 mg/kg doses in Phase I/II CLINCH study with differentiated safety profile.
• ATG-037 (Oral CD73 Inhibitor) Orally-available, highly selective small molecule CD73 inhibitor that completely blocks CD73 activity, reversing adenosine-mediated immunosuppression. Demonstrated 33.3% ORR in CPI-resistant melanoma and 21.4% ORR in CPI-resistant NSCLC.
• ATG-201 (CD19 x CD3 T-cell Engager) CD19/CD3 bispecific T-cell engager antibody targeting B cell-related autoimmune diseases, incorporating steric hindrance masking technology to eliminate CD19-expressing B cells. Out-licensed to UCB for global development.
• ATG-106 (CDH6 x CD3 T-cell Engager) CDH6 x CD3 bispecific T-cell engager for solid tumors including ovarian and kidney cancers, developed using the AnTenGager TCE 2.0 platform. Out-licensed to K2 Therapeutics for global development.
• ATG-101 (PD-L1 x 4-1BB Bispecific Antibody) PD-L1 x 4-1BB bispecific antibody for solid tumors and non-Hodgkin lymphoma, designed to overcome liver toxicity limitations of traditional 4-1BB agonists. Received U.S. FDA Orphan Drug Designation.
• ATG-125 (B7-H3 x PD-L1 Bispecific ADC) B7-H3 x PD-L1 bispecific antibody-drug conjugate for solid tumors, developed using proprietary technology with promising preclinical efficacy data.
• ATG-112 (ALPPL2 x CD3 T-cell Engager) ALPPL2 x CD3 T-cell engager for gynecological tumors and other solid malignancies, developed using the AnTenGager TCE 2.0 platform.
• ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) αCD3-TGF-β bifunctional fusion protein designed for T cell-mediated autoimmune diseases including multiple sclerosis and inflammatory bowel disease, with minimal pro-inflammatory cytokine release.
• AnTenGager TCE 2.0 Platform Proprietary T-cell engager (TCE) 2.0 platform featuring '2+1' bivalent binding for low-expressing targets, steric hindrance masking technology, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome. Licensed to partners including UCB and K2 Therapeutics for multiple bispecific programs.

Quantifiable outcome

• 46.7% and 40.0% ORR at 1.8 mg/kg and 2.4 mg/kg doses respectively for ATG-022
• +4 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Twelve partnerships are on record, tiered core, strategic and minor.

• K2 Therapeutics (MPM BioImpact)coreStrategic or Co-development Partner · 22 June 2026Exclusive license agreement for ATG-106 (CDH6 x CD3 TCE) and option for undisclosed TCE program. Antengene receives ~$20M upfront and up to $960.5M per program in milestones plus royalties. K2 obtains global rights excluding Greater China.
• UCBcoreStrategic or Co-development Partner · 3 March 2026Worldwide exclusive license agreement for ATG-201 (CD19/CD3 bispecific TCE) for autoimmune diseases. Antengene received $80M upfront and is eligible for over $1.1B in development, regulatory, and sales milestones plus tiered royalties. Antengene conducts FIH Phase I trials in China and Australia before transferring development to UCB.
• Junshi BiosciencesstrategicStrategic or Co-development Partner · 25 February 2026Clinical collaboration to evaluate ATG-037 (oral CD73 inhibitor) in combination with JS207 (PD-1/VEGF bispecific antibody) in solid tumor patients in Mainland China. Triple-axis approach targeting immune checkpoint, angiogenesis, and adenosine pathways.
• MSD (Merck & Co.)strategicStrategic or Co-development PartnerGlobal clinical collaboration to evaluate ATG-022 (CLDN18.2 ADC) in combination with KEYTRUDA (pembrolizumab) for solid tumors. Also collaboration for ATG-037 with pembrolizumab.
• Hansoh PharmacoreChannel Partner/ Reseller/ DistributorCommercialization partnership for XPOVIO (selinexor) in mainland China. Hansoh Pharma serves as the commercialization partner for this first/only-in-class XPO1 inhibitor.
• BeiGenestrategicStrategic or Co-development PartnerClinical trial collaboration to evaluate selinexor in combination with tislelizumab (anti-PD-1) for T and NK-cell lymphoma treatment.
• Karyopharm TherapeuticscoreOEM/ Whitelabel/ Licensing PartnerLicensing and collaboration agreement granting Antengene rights to develop and commercialize XPO1 inhibitors (selinexor, eltanexor, verdinexor) and ATG-019 across Asia-Pacific region.
• Calithera BiosciencescoreOEM/ Whitelabel/ Licensing PartnerWorldwide exclusive license agreement for CD73 inhibitor CB-708 (renamed ATG-037), an oral small molecule CD73 inhibitor with global rights.
• WuXi BiologicsstrategicImplementation/ SI/ Consulting PartnerStrategic cooperation for process R&D and manufacturing of innovative oncology medicines.
• WuXi STAstrategicImplementation/ SI/ Consulting PartnerStrategic cooperation for process R&D and manufacturing supporting ADC and other pipeline programs.
• LegoChem BiosciencesminorStrategic or Co-development PartnerResearch collaboration and license option agreement for new ADC candidates.
• CelularityminorStrategic or Co-development PartnerPartnership for NK cell therapy product development.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• BeiGene: Chinese-headquartered global biotech with commercial-stage oncology products (BRUKINSA, TEVIMBRA) and extensive clinical pipeline. Direct peer in commercial-stage oncology biotech with global ambitions and similar Asia Pacific commercial presence.
• Innovent Biologics: Chinese biotech with commercial oncology and autoimmune products (TYVYT/sintilimab) and bispecific antibody pipeline. Comparable as Asia Pacific-focused biotech developing innovative oncology biologics including bispecifics and ADCs.
• Junshi Biosciences: Chinese biotech with commercial PD-1 (TUOYI/toripalimab) and active clinical development of bispecific antibodies. Direct peer with overlapping clinical collaboration partnership with Antengene (JS207 combo with ATG-037).
• Hutchmed: Hong Kong-listed Chinese biotech with commercial products (ELUNATE, SULANDA) and pipeline of innovative oncology small molecules. Comparable as Asia Pacific-focused oncology biotech with HKEX listing and global development partnerships.
• Karyopharm Therapeutics: Original developer of XPOVIO (selinexor), with direct licensing partnership to Antengene for Asia Pacific rights. Direct peer with same lead molecule (selinexor) and complementary geographic focus.
• Cstone Pharmaceuticals: Chinese biotech with commercial product (GAVRETO/pritometinib) and clinical pipeline of immuno-oncology candidates. Comparable commercial-stage Chinese oncology biotech with HKEX listing and global partnerships.
• Akeso Biopharma: Chinese biotech specializing in bispecific antibodies with commercial products and deep pipeline. Highly comparable as China-based innovator developing next-generation bispecifics and TCEs for oncology and autoimmune diseases.
• RemeGen: Chinese biotech with commercial biologics (disitamab vedotin, telitacicept) and ADC pipeline. Direct peer in commercial-stage Chinese biotech developing antibody-drug conjugates and innovative biologics.

Regional players

• Hansoh Pharmaceutical: Major Chinese pharma with established commercial infrastructure and Antengene's XPOVIO commercialization partner in mainland China. Comparable as China-headquartered commercial pharma partner with biopharma capabilities.

Emerging players

• Genor Biopharma: Chinese biotech developing innovative oncology therapies including ADCs and bispecific antibodies. Comparable emerging China-based oncology biotech with similar focus on innovative biologic modalities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/antengene-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Antengene